Cross-reactivity to porcine factor VIII of factor VIII inhibitors in patients with haemophilia in Australia and New Zealand

Australian and New Zealand Journal of Medicine

Volumn 27, Issue 6, 1997, Pages 658-664

  Lloyd, J V ^a,l   Street, A M ^b,l   Berry, E ^c,m   McPherson, J ^d,l   Ekert, H ^e,l   Lammi, A ^f,l   McWhirter, W R ^g,l   Duncan, E M ^a   Maxwell, E L ^b,l   Rowell, J ^h,l   Baker, R I ^i,l   Leahy, M F ^j,l   Jupe, D ^k,l  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d NEWCASTLE MATER HOSPITAL   (Australia)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

^f CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^g ROYAL CHILDREN'S HOSPITAL   (Australia)

^h ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

ⁱ ROYAL PERTH HOSPITAL   (Australia)

^j FREMANTLE HOSPITAL   (Australia)

^k ROYAL HOBART HOSPITAL   (Australia)

^l Australian Med Advsy Panel H

^m New Zealand Med Advsy Panel H

more..

Author keywords

Acquired haemophilia; Cross reactivity; Factor VIII inhibitors; Haemophilia; Human factor VIII; Inherited haemophilia; Porcine factor VIII

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY;

ANTIBODY SPECIFICITY; ARTICLE; AUSTRALIA; CROSS REACTION; DISEASE SEVERITY; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; NEW ZEALAND;

EID: 15444352443     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1997.tb00994.x     Document Type: Article

References (21)

1. Hoyer LW. Annotation: Why do so many haemophilia A patients develop an inhibitor? Br J Haematol 1995; 90: 498-501.
2. Briet E, Rosendaal FR, Kreuz W et al. High titre inhibitors in severe haemophilia A: A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products. Thromb Haemost 1994; 72: 162-4.
3. Schwaab R, Brackmann HH, Meyer C et al. Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
4. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200-3.
5. Lottenberg R, Tenney B, Kentro TB, Kitchens CS. Acquired hemophilia: A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147: 1077-81.
6. Hay CRM, Lozier JN, Lee CA et al. Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: Efficacy, patient selection, and side effects. Semin Hematol 1994; 31 (Suppl. 4): 20-5.
7. Fiks-Siaud M, Berdelac L, Parquet A et al. Comparison of anti-human and anti-porcine factor VIII inhibitor levels in 63 patients with severe haemophilia A. Vox Sang 1993; 64: 210-4.
8. Lusher JM. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors - benefits and limitations. Semin Hematol 1994; 31 (Suppl. 4): 49-52.
9. McPherson J, Teague L, Lloyd JV et al. Experience with recombinant factor VIIa in Australia and New Zealand. Haemostasis 1996; 26 (Suppl. 1): 109-17.
10. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the international registry: Report of the factor VIII and IX subcommittee. Thromb Haemost 1994; 72: 155-8.
11. Lian ECY, Larcada AF, Chiu AYZ. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med 1989; 110: 774-8.
12. Kasper CK, Aledort LM, Counts RB et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72.
13. Goldsmith JC. Diagnosis of factor VIII versus nonspecific inhibitors. Semin Haematol 1993; 30 (Suppl. 1): 3-6.
14. Brettler DB, Levine PH. Clinical manifestations and therapy of inherited coagulation factor deficiencies. In: Colman RW, Hirsch J, Marder V, Salzman EW (Eds). Haemostasis and thrombosis: Basic principles and clinical practice. 3rd edn. Philadelphia: J. B. Lippincott & Co, 1994: 169-70.
15. Verbruggen B, Novakova I, Wessels H, Boezman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
16. Mannucci PM, Tripodi A. Factor VIII clotting activity. In: ECAT Assay Procedures: A manual of laboratory techniques. 1st edn. Dordrecht: Kluwer Academic Publishers, 1992: 65-70.
17. Gatti L, Mannucci PM. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies. Thromb Haemost 1984; 51: 379-84.
18. Wion K, Tuddenham E, Lawn R. A new polymorphism in the factor VIII gene for prenatal diagnosis of hemophilia. Nucleic Acids Res 1986; 14: 4535-42.
19. Kessler GM. Factor VIII inhibitors - An algorithmic approach to treatment. Semin Haematol 1994; 31 (Suppl. 4): 33-6.
20. Millar DS, Kakkar VV, Cooper DN. Screening for inversions in the factor VIII (F8) gene causing severe haemophilia A. Blood Coagulation and fibrinolysis 1994; 5: 239-42.
21. Hay CRM, Lozier JN, Lee CA et al. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia A and inhibitors: the results of an international survey. Thromb Haemost 1996; 75: 25-9.